
Claims

1. A compound of Formula (I)

A-B-C (I)

or a pharmaceutically acceptable salt, tautomeric forms or stereoisomers thereof, wherein A is of the following:



wherein the wavy line indicates the point of attachment to B;

X^1 is N;

R^{A2} is selected from the group consisting of:

(i) H;

(ii) halo;

(iii) CN;

(iv) C_{1-6} hydrocarbon, optionally substituted by OH, CN, C_{1-6} acyl, C_{1-6} alkoxy or one or more halo groups;

(v) C_{1-6} alkoxy, optionally substituted by OH, alkyl amido, or one or more halo groups;

(vi) C_{1-6} acyl amido (wherein the acyl is optionally substituted by H or methyl);

(vii) C_{1-6} thioalkyl;

(viii) C_{1-6} alkyl ester;

(ix) C_{1-6} alkyl acyl;

(x) C_{4-5} heterocyclyl;

(xi) C_5 heteroaryl;

(xii) C_{1-6} alkyl amido optionally substituted by C_{1-3} alkyl amido, CN, OH, C_{2-3} alkynyl, C_{4-6} heterocyclyl or C_{1-3} alkyl wherein the C_{1-3} alkyl is optionally substituted with one or more halo or OH groups; and

(xiii) OH; and

(xiv) C_{1-6} alkylamino;

R^{A3} is selected from the group consisting of:


(i) H;
(ii) halo;
(iii) CN;
(iv) C_{1-6} hydrocarbon optionally substituted by OH, CN, C_{1-6} thioalkyl, C_{1-6} alkoxy, C_{1-6} alkyl acyl, C_{1-6} acyloxy, carboxy, C_{1-6} alkyl ester, C_{1-6} alkylamino, -C(=O)NH_2, C_{1-6} alkyl amido, C_{1-6} alkyl acylamido, C_{1-6} alkyl sulfinyl, C_{1-6} alkyl sulfonyl or one or more halo groups;
(v) OH;
(vi) C_{1-6} alkoxy, optionally substituted by OH, NH_2, C_4 heterocyclyl or one or more halo groups;
(vii) C_{1-6} acyloxy;
(viii) C_4 heterocycyl;
(ix) -NH_2;
(x) C_{1-6} alkylamino, optionally substituted by CN, OH or C_4 heterocyclyl;
(xi) C_{1-6} dialkylamino, optionally substituted by -NH_2;
(xii) C_{1-6} acylamido (where acyl substituent is H or Me);
(xiii) carbaimidoyl or methyl-carbaimidoyl;
(xiv) carboxyamino;
(xv) C_{1-6} thioalkyl, optionally substituted by OH or -NH_2;
(xvi) C_{1-6} alkyl sulfinyl;
(xvi) C_{1-6} alkyl sulfonyl, optionally substituted by one or more halo groups;
(xvii) C_{1-6} sulfonimodyl;
(xviii) C_{1-6} alkyl phosphinyl;
(xix) carboxy;
(xx) -C(=O)NH_2
(xxi) C_{1-6} alkyl ester;
(xxii) C_{1-6} alkyl acyl, optionally substituted by one or more halo groups;
(xxiii) C_{1-6} alkyl amido;

or wherein R^{A3} and R^{A2} together with the carbon atoms to which they are bound form:
(i) an optionally substituted C_{5-7} heterocycle ring;
(ii) an optionally substituted C_{5-7} heteroaromatic ring;
(iii) an optionally substituted C_6 carboaromatic ring;
(iv) an optionally substituted C_{5-7} carbocyclic ring

wherein the optional substituents are selected from C_{1-6} alkyl, halo, C_{1-6} alkoxy, -NH_2, C_{1-6} alkylamino, OH, and CN;

wherein B is of formula (B-1) or (B-2)

i)




(B-1)

wherein the wavy line indicates the point of attachment to A and C;

R^{B1} is H, OH, =CHCH$_2$-OH, -O-C$_{1-4}$ alkyl or C$_{1-4}$ alkyl, wherein the C$_{1-4}$ alkyl is optionally substituted by OH or OMe;

(ii)



(B-2)

wherein the wavy line indicates the point of attachment to A and C;

R^{B2} is C$_{1-2}$ alkyl-OH, CH$_2$C(=O)NHMe or C$_{1-3}$ alkyl;

wherein C is selected from the group consisting of C$_{6-10}$ carboaryl, C$_{5-6}$ heteroaryl and C$_{5-10}$ heterocyclyl, which groups are optionally substituted by:

(i) C$_{6-10}$ carboaryl, C$_{4-10}$ carbocyclyl, C$_{5-10}$ heteroaryl, C$_{4-10}$ heterocyclyl, or C$_{5-10}$ bridged heterocyclyl, spiro C$_{6-12}$ heterocyclyl or a spiro C$_{6-12}$ carbocyclyl,

which are themselves optionally substituted by one or more of the following groups:

a) one or two =O groups;

b) one or more halo groups;

c) CN, NH$_2$, OH;

d) one or more C$_{1-6}$ alkyl groups including branched and cyclic and with an optional substituent selected from OH or one or more halo groups;

e) C$_{1-6}$ alkoxy with optional substituents of one or more halo groups;

f) C$_{1-6}$ alkylester;

g) C$_{5-6}$ heterocyclyl with an optional methyl, OH or =O substituent;

h) C$_{5-6}$ heteroaryl;

i) C$_{4-10}$ carbocyclyl with an optional methyl or =O substituent;

j) C$_{6-10}$ carboaryl with optional substituents of one or more halo groups;

l) P(=O)Me$_2$;

m) carboxy or CH$_2$-carboxy;

n) tetrazolyl, CH$_2$-tetrazolyl, 5-oxo-4H-1,2,4-oxadiazol-3-yl;


(ii) one or more groups selected from carboxy, CN, halo, nitro, C_{1-6} alkyl, C_{1-6} thioalkyl, C_{1-6} alkoxy, C_{1-6} alkylacyl, C_{1-6} alkyl amido, di-C_{1-6} alkyl amido, C_{1-6} alkyl sulfonamido, and di-C_{1-6} alkyl sulfonamido.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R^{A2} is selected from the group consisting of -C(=O)OCH_2CH_3, cyclopropyl, methyl, H, Cl, -C(=O)CH_3, -S-ethyl, pyrazole, -$N(CH_3)_2$, -C(=O)$NH(CH_2C(=O)NH_2$, -C(=O)$NHCH_2C{\equiv}CH$, -C(=O)NH(oxetane), -C(=O)$NH(CH_2CHF_2)$, -C(=O)$NH(CH_2CH_3)$, -C(=O)NH_2, -C(=O)$NH(CH_3)$, -C(=O)$N(CH_3)_2$, -C(=O)$N(CH_3)(CH_2CH_2OH)$, -C(=O)$N(CH_3)(CH_2C{\equiv}CH)$ or -C(=O)$NH(CH_2CH_2OH)$.

3. The compound of either of claims 1 or 2 or a pharmaceutically acceptable salt thereof, wherein R^{A3} is selected from the group consisting of H, methyl and OH.


4. The compound of any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof, wherein B is of the following formula:

a)



(B-1a); or

b)



.

5. The compound of any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof, wherein C is an optionally substituted pyridinyl, pyrazinyl or pyrimidinyl, wherein the optional substituents are selected from C_{6-10} carboaryl, C_{4-10} carbocyclyl, C_{5-10} heteroaryl, C_{5-10} heterocyclyl, C_{5-10} bridged heterocyclyl, spiro C_{6-12} heterocyclyl or a spiro C_{6-12} carbocyclyl, which are themselves optionally substituted by one or more of the following groups:

a) one or two =O groups;

b) one or more halo groups;

c) CN, NH_2 or OH;

d) one or more C_{1-6} alkyl groups including branched and cyclic and with an optional substituent selected from OH or one or more halo groups;

e) C_{1-6} alkoxy with optional substituents of one or more halo groups;

f) C_{1-6} alkylester;

g) C_{5-6} heterocyclyl with an optional methyl, OH or =O substituent;

h) C_{5-6} heteroaryl;

i) C_{4-10} carbocyclyl with an optional methyl or =O substituent;


j) C_{6-10} carboaryl with optional substituents of one or more halo groups;

l) $P(=O)Me_2$;

m) carboxy or CH_2-carboxy; and/or

n) tetrazolyl, CH_2-tetrazolyl, 5-oxo-4H-1,2,4-oxadiazol-3-yl.

6. The compound of any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof, wherein C is of the formula (C-1):



(C-1)

wherein D is C_{6-10} carboaryl, C_{5-10} heteroaryl or C_{5-10} heterocyclyl, each which are themselves optionally substituted by:

i) one or two =O groups;

ii) one or two C_{1-4} alkyl groups which can be branched;

iii) OMe;

iv) piperazinyl, optionally substituted by methyl;

v) C(=O)OH (carboxy);

vi) Cl;

vii) F;

viii) phenyl, optionally substituted by one or more fluoro;

ix) CN;

x) CF_3;

xi) O-CF_3;

xii) tetrazolyl, pyrazolyl, triazolyl each of which is optionally substituted by methyl;

xiii) NH_2;

xiv) pyridinyl;


xv) CH_2OH;

xvi) OH;

xvii) $P(=O)Me_2$; or

xviii) $OCHF_2$.

7. The compound of claim 6 or a pharmaceutically acceptable salt thereof, wherein D is of the formula (D-1):



(D-1)

wherein one or two of R^{D1}, R^{D2}, R^{D3} and R^{D4} are selected from

i) C_{1-6} alkyl, optionally substituted by one or more halo groups;

ii) C_{1-6} alkoxy, optionally substituted by one or more halo groups;

iii) C_{5-6} heterocyclyl or C_{5-6} heteroaryl with an optional methyl substituent;

iv) carboxy or CH_2-carboxy;

v) =O, halo, NH_2 or CN;


vi) phenyl, optionally substituted by one or more halo atoms;

and the rest are H; or

wherein R^{D3} and R^{D4} form an optionally substituted 6 membered carboaromatic, heterocycle or heteroaromatic ring, wherein the optional substituents are selected from OH, methyl, OMe, halo and C(=O)OH;

or wherein R^{D1}, R^{D2}, R^{D3} and R^{D4} are all H.

8. The compound of claim 6 or a pharmaceutically acceptable salt thereof, wherein D is of the formula (D-2):



(D-2)

wherein X^D is NR^{D5a} or $CR^{D5a}R^{D5b}$;

R^{D5a} is selected from H or methyl;

either R^{D5b} and R^{D6b} are both H or together they are $-CH_2-$;


R^{D6a} is selected from H, =O, methyl, $-CH_2OH$ or -C(=O)OH, wherein when R^{D6a} is =O, R^{D6b} is absent;

R^{D7a} is selected from H, =O, methyl, $-CH_2OH$ or -C(=O)OH;

R^{D7b} is H, wherein when R^{D7a} is =O, R^{D7b} is absent;

or wherein R^{D6a} and R^{D7a} together form a benzene ring or a C_6 heteroaromatic ring which is optionally substituted by CN, $P(=O)Me_2$ or carboxy and R^{D6b} and R^{D7b} are absent.

9. The compound of any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof, wherein C is of the formula (C-2):




(C-2)


wherein one of R^{C7}, R^{C8}, R^{C9} and R^{C10} are selected from the group consisting of: methyl; OMe; piperazinyl optionally substituted by methyl; C(=O)OH (carboxy); Cl; F; pyrazolyl optionally substituted by methyl; triazolyl; tetrazole; optionally substituted phenyl (wherein the optional substituent is methyl or halo); CN; CF_3; $O\text{-}CHF_2$, $O\text{-}CF_3$; and the rest of R^{C7}, R^{C8}, R^{C9} and R^{C10} are H; or

R^{C9} and R^{C10} form a benzene or 6 membered heteroaromatic ring, and R^{C7} and R^{C8} are both H; or wherein R^{C7}, R^{C8}, R^{C9} and R^{C10} are all H.


10. The compound of any of the preceding claims or a pharmaceutically acceptable salt thereof, wherein A-B-C is of the formula (I-A), (I-B), (I-Ba), (I-Bb), (I-C), (I-D), (I-E), (I-Ea) or (I-Eb):




(I-A),




(I-B),




(I-Ba),




(I-Bb),




(I-C),




(I-D),



(I-E);









(I-Ea);

















(I-Eb),








wherein X^1, R^{A2}, R^{A3}, C, D, R^{D1}, R^{D2}, R^{D3}, R^{D4}, R^{D1a}, R^{D2a}, R^{D3a}, R^{D4a}, X^D, R^{D6a}, R^{D6b} and R^{D7a} are as defined in any of the preceding claims.








11. The compound which is








Ex	Structure	Name
10		Ethyl 3-(((1*S*,3*S*)-3-((2-oxo-2*H*-[1,3'-bipyridin]-6'-yl)amino)cyclopentyl)amino)-1,2,4-triazine-6-carboxylate
50		6'-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2*H*-[1,3'-bipyridin]-2-one
51		6'-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-3-(trifluoromethyl)-2*H*-[1,3'-bipyridin]-2-one
52		6'-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-3-(trifluoromethoxy)-2*H*-[1,3'-bipyridin]-2-one
53		(1*S*,3*S*)-N^1-(6-Cyclopropyl-1,2,4-triazin-3-yl)-N^3-(5-(2,6-difluorophenyl)pyridin-2-yl)cyclopentane-1,3-diamine
54		(1*S*,3*S*)-N^1-(6-Cyclopropyl-1,2,4-triazin-3-yl)-N^3-(5-(2-fluoro-6-methoxyphenyl)pyridin-2-yl)cyclopentane-1,3-diamine








Ex	Structure	Name
55		3-Chloro-6'-(((1*S*,3*S*)-3-((6-cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2*H*-[1,3'-bipyridin]-2-one
56		6'-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2-oxo-2*H*-[1,3'-bipyridine]-5-carbonitrile
57		3-(6-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyridin-3-yl)-1-methylimidazolidine-2,4-dione
58		6'-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2-oxo-2*H*-[1,3'-bipyridine]-3-carbonitrile
59		2-(5-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyrazin-2-yl)pyridazin-3(2*H*)-one
60		6'-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-1-methyl-[3,3'-bipyridin]-2(1*H*)-one
61		6'-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-3-fluoro-[2,3'-bipyridine]-6-carbonitrile








Ex	Structure	Name
62		1-(6-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyridin-3-yl)-3-methylimidazolidine-2,4-dione
63		3-(6-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyridin-3-yl)-1-methyl-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one
64		6'-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-3-methoxy-2*H*-[1,3'-bipyridin]-2-one
65		6'-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-5-methoxy-2*H*-[1,3'-bipyridin]-2-one
66		6'-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-3-methyl-2*H*-[1,3'-bipyridin]-2-one
67		6'-(((1*S*,3*S*)-3-((6-Methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2*H*-[1,3'-bipyridin]-2-one
68		*N*-(2-Amino-2-oxoethyl)-3-(((1*S*,3*S*)-3-((2-oxo-2*H*-[1,3'-bipyridin]-6'-yl)amino)cyclopentyl)amino)-1,2,4-triazine-6-carboxamide






Ex	Structure	Name
69		3-(((1*S*,3*S*)-3-((2-Oxo-2*H*-[1,3'-bipyridin]-6'-yl)amino)cyclopentyl)amino)-*N*-(prop-2-yn-1-yl)-1,2,4-triazine-6-carboxamide
70		*N*-(Oxetan-3-yl)-3-(((1*S*,3*S*)-3-((2-oxo-2*H*-[1,3'-bipyridin]-6'-yl)amino)cyclopentyl)amino)-1,2,4-triazine-6-carboxamide
71		*N*-(2,2-Difluoroethyl)-3-(((1*S*,3*S*)-3-((2-oxo-2*H*-[1,3'-bipyridin]-6'-yl)amino)cyclopentyl)amino)-1,2,4-triazine-6-carboxamide
72		*N*-(2-Hydroxyethyl)-3-(((1*S*,3*S*)-3-((2-oxo-2*H*-[1,3'-bipyridin]-6'-yl)amino)cyclopentyl)amino)-1,2,4-triazine-6-carboxamide
73		*N*-Ethyl-3-(((1*S*,3*S*)-3-((2-oxo-2*H*-[1,3'-bipyridin]-6'-yl)amino)cyclopentyl)amino)-1,2,4-triazine-6-carboxamide
74		3-(((1*S*,3*S*)-3-((2-Oxo-2*H*-[1,3'-bipyridin]-6'-yl)amino)cyclopentyl)amino)-1,2,4-triazine-6-carboxamide
75		*N*-Methyl-3-(((1*S*,3*S*)-3-((2-oxo-2*H*-[1,3'-bipyridin]-6'-yl)amino)cyclopentyl)amino)-1,2,4-triazine-6-carboxamide







Ex	Structure	Name
76		*N*,*N*-Dimethyl-3-(((1*S*,3*S*)-3-((2-oxo-2*H*-[1,3'-bipyridin]-6'-yl)amino)cyclopentyl)amino)-1,2,4-triazine-6-carboxamide
Ex	**Structure**	**Name**
112		5-Chloro-6'-(((1*S*,3*S*)-3-((6-cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2*H*-[1,3'-bipyridin]-2-one
113		3-(5-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyrazin-2-yl)-1-methylpyridin-2(1*H*)-one
114		3-(6-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyridin-3-yl)pyrimidin-4(3*H*)-one
115		3-(2-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyrimidin-5-yl)-1-methylpyridin-2(1*H*)-one
116		3-(6-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyridin-3-yl)-1-methyl-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carbonitrile
117		1-(6-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carbonitrile








Ex	Structure	Name
118		2-(6-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyridin-3-yl)pyridazin-3(2*H*)-one
119		2-(2-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyrimidin-5-yl)pyridazin-3(2*H*)-one
120		2'-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-6*H*-[1,5'-bipyrimidin]-6-one
121		1-(6-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxylic acid
122		6'-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-5-(1*H*-1,2,3-triazol-4-yl)-2*H*-[1,3'-bipyridin]-2-one
123		6'-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-5-(1*H*-pyrazol-4-yl)-2*H*-[1,3'-bipyridin]-2-one
124		6'-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-5-(1*H*-tetrazol-5-yl)-2*H*-[1,3'-bipyridin]-2-one








Ex	Structure	Name
125		3-(6-(((1*S*,3*S*)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyridin-3-yl)-5-(dimethylphosphoryl)-1-methyl-1,3-dihydro-2*H*-benzo[*d*]imidazol-2-one
126		6'-(((1*S*,3*S*)-3-((5-Methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2*H*-[1,3'-bipyridin]-2-one
127		6'-(((1*S*,3*S*)-3-((5,6-Dimethyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2*H*-[1,3'-bipyridin]-2-one
128		6'-(((1*S*,3*S*)-3-((6-Methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2-oxo-2*H*-[1,3'-bipyridine]-5-carbonitrile
129		3-Chloro-6'-(((1*S*,3*S*)-3-((6-methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2*H*-[1,3'-bipyridin]-2-one
130		5-Methyl-6'-(((1*S*,3*S*)-3-((6-methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2*H*-[1,3'-bipyridin]-2-one
131		3-Methyl-6'-(((1*S*,3*S*)-3-((6-methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2*H*-[1,3'-bipyridin]-2-one







Ex	Structure	Name
132		3-Methoxy-6'-(((1*S*,3*S*)-3-((6-methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2*H*-[1,3'-bipyridin]-2-one
133		5-Methoxy-6'-(((1*S*,3*S*)-3-((6-methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2*H*-[1,3'-bipyridin]-2-one
134		5-Chloro-6'-(((1*S*,3*S*)-3-((6-methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2*H*-[1,3'-bipyridin]-2-one
135		6'-(((1*S*,3*S*)-3-((6-Methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-3-(trifluoromethyl)-2*H*-[1,3'-bipyridin]-2-one
136		6'-(((1*S*,3*S*)-3-((6-Methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2-oxo-2*H*-[1,3'-bipyridine]-3-carbonitrile
137		3-Fluoro-6'-(((1*S*,3*S*)-3-((6-methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2*H*-[1,3'-bipyridin]-2-one
138		6'-(((1*S*,3*S*)-3-((6-Methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-3-(trifluoromethoxy)-2*H*-[1,3'-bipyridin]-2-one








Ex	Structure	Name
151		N-(2-Hydroxyethyl)-N-methyl-3-(((1S,3S)-3-((2-oxo-2H-[1,3'-bipyridin]-6'-yl)amino)cyclopentyl)amino)-1,2,4-triazine-6-carboxamide
152		N-Methyl-3-(((1S,3S)-3-((2-oxo-2H-[1,3'-bipyridin]-6'-yl)amino)cyclopentyl)amino)-N-(prop-2-yn-1-yl)-1,2,4-triazine-6-carboxamide
153		3-(((1S,3S)-3-((3-Methoxy-2-oxo-2H-[1,3'-bipyridin]-6'-yl)amino)cyclopentyl)amino)-N-(oxetan-3-yl)-1,2,4-triazine-6-carboxamide
154		3-(((1S,3S)-3-((5-Methoxy-2-oxo-2H-[1,3'-bipyridin]-6'-yl)amino)cyclopentyl)amino)-N-(oxetan-3-yl)-1,2,4-triazine-6-carboxamide
155		3-(((1*S*,3S)-3-((3-Methyl-2-oxo-2*H*-[1,3'-bipyridin]-6'-yl)amino)cyclopentyl)amino)-*N*-(oxetan-3-yl)-1,2,4-triazine-6-carboxamide









Ex	Structure	Name
156		3-(((1S,3S)-3-((5-Methyl-2-oxo-2H-[1,3'-bipyridin]-6'-yl)amino)cyclopentyl)amino)-N-(oxetan-3-yl)-1,2,4-triazine-6-carboxamide
157		3-(((1S,3S)-3-((3-Chloro-2-oxo-2H-[1,3'-bipyridin]-6'-yl)amino)cyclopentyl)amino)-N-(oxetan-3-yl)-1,2,4-triazine-6-carboxamide
158		3-(((1S,3S)-3-((5-Chloro-2-oxo-2H-[1,3'-bipyridin]-6'-yl)amino)cyclopentyl)amino)-N-(oxetan-3-yl)-1,2,4-triazine-6-carboxamide
159		3-(((1S,3S)-3-((3-Cyano-2-oxo-2H-[1,3'-bipyridin]-6'-yl)amino)cyclopentyl)amino)-N-(oxetan-3-yl)-1,2,4-triazine-6-carboxamide
160		N-(Oxetan-3-yl)-3-(((1S,3S)-3-((2-oxo-3-(trifluoromethoxy)-2H-[1,3'-bipyridin]-6'-yl)amino)cyclopentyl)amino)-1,2,4-triazine-6-carboxamide
161		N-(Oxetan-3-yl)-3-(((1S,3S)-3-((2-oxo-3-(trifluoromethyl)-2H-[1,3'-bipyridin]-6'-yl)amino)cyclopentyl)amino)-1,2,4-triazine-6-carboxamide









Ex	Structure	Name
165		6'-(((1S,3S)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-3-(difluoromethoxy)-2H-[1,3'-bipyridin]-2-one
166		6'-(((1S,3S)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-5-(difluoromethoxy)-2H-[1,3'-bipyridin]-2-one
167		3-(6-(((1S,3S)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyridin-3-yl)-4-fluoro-2-methoxybenzoic acid
168		3-(6-(((1S,3S)-3-((6-Cyclopropyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyridin-3-yl)-4-fluoro-2-methoxybenzonitrile
169		(1S,3S)-N1-(6-Cyclopropyl-1,2,4-triazin-3-yl)-N3-(5-(6-fluoro-2-methoxy-3-(1H-tetrazol-5-yl)phenyl)pyridin-2-yl)cyclopentane-1,3-diamine
173		*rel*-3-Methyl-6'-(((1*R*,3*R*)-3-((6-methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2*H*-[1,3'-bipyridin]-2-one
180		4-Methoxy-6'-(((1S,3S)-3-((6-methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2H-[1,3'-bipyridin]-2-one








Ex	Structure	Name
182		4-Chloro-6'-(((1S,3S)-3-((6-methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2H-[1,3'-bipyridin]-2-one
183		6'-(((1S,3S)-3-((6-Methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2-oxo-2H-[1,3'-bipyridine]-4-carbonitrile
185		5-(Difluoromethoxy)-6'-(((1S,3S)-3-((6-methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2H-[1,3'-bipyridin]-2-one
187		3-(Difluoromethoxy)-6'-(((1S,3S)-3-((6-methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2H-[1,3'-bipyridin]-2-one
197		1-(6-(((1S,3S)-3-((6-Methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyridin-3-yl)-1,8-naphthyridin-2(1H)-one
198		6'-(((1S,3S)-3-((6-Methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-3-(1-methyl-1H-pyrazol-4-yl)-2H-[1,3'-bipyridin]-2-one
199		6'-(((1S,3S)-3-((6-Methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-3-(1H-pyrazol-4-yl)-2H-[1,3'-bipyridin]-2-one






Ex	Structure	Name
200		6'-(((1S,3S)-3-((6-Methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-3-(1H-1,2,3-triazol-4-yl)-2H-[1,3'-bipyridin]-2-one
201		6'-(((1S,3S)-3-((6-Methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-5-(1-methyl-1H-pyrazol-4-yl)-2H-[1,3'-bipyridin]-2-one
202		6'-(((1S,3S)-3-((6-Methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-5-(1H-pyrazol-4-yl)-2H-[1,3'-bipyridin]-2-one
208		6'-(((1S,3S)-3-((6-Methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-5-(1H-1,2,3-triazol-4-yl)-2H-[1,3'-bipyridin]-2-one
210		1-Methyl-3-(6-(((1S,3S)-3-((6-methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyridin-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carbonitrile
211		3-Methyl-1-(6-(((1S,3S)-3-((6-methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyridin-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carbonitrile


Ex	Structure	Name
212		1-Methyl-3-(6-(((1S,3S)-3-((6-methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one
213		1-Methyl-3-(6-(((1S,3S)-3-((6-methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyridin-3-yl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine-5-carbonitrile
214		1-Methyl-3-(6-(((1S,3S)-3-((6-methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyridin-3-yl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine-6-carbonitrile
220		4-Methoxy-2-(6-(((1S,3S)-3-((6-methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyridin-3-yl)pyridazin-3(2H)-one
221		4-Chloro-2-(6-(((1S,3S)-3-((6-methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyridin-3-yl)pyridazin-3(2H)-one
222		6-Chloro-2-(6-(((1S,3S)-3-((6-methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyridin-3-yl)pyridazin-3(2H)-one
247		2-(6-(((1S,3S)-3-((6-Methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyridin-3-yl)benzonitrile

Ex	Structure	Name
248		(1S,3S)-N1-(6-Methyl-1,2,4-triazin-3-yl)-N3-(3-methyl-[2,3'-bipyridin]-6'-yl)cyclopentane-1,3-diamine
249		(1S,3S)-N1-(5-(3,5-Dimethyl-1H-pyrazol-1-yl)pyridin-2-yl)-N3-(6-methyl-1,2,4-triazin-3-yl)cyclopentane-1,3-diamine
250		2,4-Dimethyl-1-(6-(((1S,3S)-3-((6-methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyridin-3-yl)-1H-imidazole-5-carbonitrile
254		6'-(((1S,3S)-3-((6-Methyl-5-oxo-4,5-dihydro-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2H-[1,3'-bipyridin]-2-one
255		6'-(((1S,3S)-3-((6-Chloro-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2H-[1,3'-bipyridin]-2-one
256		6'-(((1S,3S)-3-((6-(Dimethylamino)-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2H-[1,3'-bipyridin]-2-one
257		6'-(((1S,3S)-3-((6-(1H-Pyrazol-5-yl)-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2H-[1,3'-bipyridin]-2-one
258		6'-(((1S,3S)-3-((6-(Ethylthio)-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2H-[1,3'-bipyridin]-2-one

Ex	Structure	Name
260		6'-(((1S,3S)-3-((6-Acetyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)-2H-[1,3'-bipyridin]-2-one
277		2-(6-(((1S,3S)-3-((6-Methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyridin-3-yl)-3-oxo-2,3-dihydropyridazine-4-carbonitrile
281		4-(Difluoromethoxy)-2-(6-(((1S,3S)-3-((6-methyl-1,2,4-triazin-3-yl)amino)cyclopentyl)amino)pyridin-3-yl)pyridazin-3(2H)-one
304		(1S,3S)-N1-(3-Methoxy-[2,3'-bipyridin]-6'-yl)-N3-(6-methyl-1,2,4-triazin-3-yl)cyclopentane-1,3-diamine
305		(1S,3S)-N1-(6-Methoxy-[2,3'-bipyridin]-6'-yl)-N3-(6-methyl-1,2,4-triazin-3-yl)cyclopentane-1,3-diamine
306		(1S,3S)-N1-(5-(2-Methoxyphenyl)pyridin-2-yl)-N3-(6-methyl-1,2,4-triazin-3-yl)cyclopentane-1,3-diamine
307		(1S,3S)-N1-(5-(2,6-Dimethoxyphenyl)pyridin-2-yl)-N3-(6-methyl-1,2,4-triazin-3-yl)cyclopentane-1,3-diamine
308		(1S,3S)-N1-(5-(2-Fluoro-6-methoxyphenyl)pyridin-2-yl)-N3-(6-methyl-1,2,4-triazin-3-yl)cyclopentane-1,3-diamine

Ex	Structure	Name
309		(1S,3S)-N1-([2,3'-Bipyridin]-6'-yl)-N3-(6-methyl-1,2,4-triazin-3-yl)cyclopentane-1,3-diamine
310		(1S,3S)-N1-(5-(1H-Pyrazolo[3,4-b]pyridin-1-yl)pyridin-2-yl)-N3-(6-methyl-1,2,4-triazin-3-yl)cyclopentane-1,3-diamine
311		(1S,3S)-N1-(5-(1H-Indazol-1-yl)pyridin-2-yl)-N3-(6-methyl-1,2,4-triazin-3-yl)cyclopentane-1,3-diamine
312		(1S,3S)-N1-(5-(2H-Indazol-2-yl)pyridin-2-yl)-N3-(6-methyl-1,2,4-triazin-3-yl)cyclopentane-1,3-diamine
313		(1S,3S)-N1-(5-(3,5-Dimethyl-1H-1,2,4-triazol-1-yl)pyridin-2-yl)-N3-(6-methyl-1,2,4-triazin-3-yl)cyclopentane-1,3-diamine
314		(1S,3S)-N1-(5-(2,5-Dimethyloxazol-4-yl)pyridin-2-yl)-N3-(6-methyl-1,2,4-triazin-3-yl)cyclopentane-1,3-diamine
315	AND Enantiomer 	rac-(R)-6'-((4-Hydroxy-2-(((6-methyl-1,2,4-triazin-3-yl)amino)methyl)butyl)amino)-3-methyl-2H-[1,3'-bipyridin]-2-one

Ex	Structure	Name
316	AND Enantiomer 	rac-(R)-6'-((4-Hydroxy-2-(((6-methyl-1,2,4-triazin-3-yl)amino)methyl)butyl)amino)-5-methyl-2H-[1,3'-bipyridin]-2-one
317	AND Enantiomer 	rac-(R)-6'-((4-Hydroxy-2-(((6-methyl-1,2,4-triazin-3-yl)amino)methyl)butyl)amino)-5-methoxy-2H-[1,3'-bipyridin]-2-one
318	AND Enantiomer 	rac-(R)-1-(6-((4-Hydroxy-2-(((6-methyl-1,2,4-triazin-3-yl)amino)methyl)butyl)amino)pyridin-3-yl)quinolin-2(1H)-one
319	AND Enantiomer 	rac-(R)-3-(6-((4-Hydroxy-2-(((6-methyl-1,2,4-triazin-3-yl)amino)methyl)butyl)amino)pyridin-3-yl)-1-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one
320	AND Enantiomer 	rac-(R)-1-(6-((4-Hydroxy-2-(((6-methyl-1,2,4-triazin-3-yl)amino)methyl)butyl)amino)pyridin-3-yl)-1,8-naphthyridin-2(1H)-one

Ex	Structure	Name
321	AND Enantiomer 	rac-(R)-1-(6-((4-Hydroxy-2-(((6-methyl-1,2,4-triazin-3-yl)amino)methyl)butyl)amino)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one

or a pharmaceutically acceptable salt thereof.

12. The compound of any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof, for use in therapy.

13. A pharmaceutical composition comprising the compound of any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent, carrier or excipient.

14. The compound of any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 13 for use in the treatment of a cardiovascular disease optionally wherein the cardiovascular disease is selected from dyslipidemia, hypercholesterolemia, hypertriglyceridemia, hyperlipidemia, hypoalphalipoproteinemia, metabolic syndrome, diabetic complications, atherosclerosis, stroke, vascular dimensia, chronic kidney disease, coronary heart disease, coronary artery disease, retinopathy, inflammation, thrombosis, peripheral vascular disease heart failure or congestive heart failure.

15. The compound or a pharmaceutically acceptable salt thereof, for use according to claim 14 wherein the compound is to be administered simultaneously, separately or sequentially in combination with an additional active ingredient selected from the group consisting of:

i) a statin;
ii) a cholesterol absorption inhibitor;
iii) a SGLT2 inhibitor;
iv) a P2Y12 inhibitor;
v) a citrate lyase inhibitor; and
vi) anti-hypertensive drugs.